Format

Send to

Choose Destination
Trends Immunol. 2001 May;22(5):269-76.

The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity.

Author information

1
The Center for Cell and Gene Therapy, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA. rongfuw@bcm.tmc.edu

Abstract

The identification of tumor antigens has generated a resurgence of interest in immunotherapy for cancer. However, both clinical and animal studies suggest that therapeutic strategies that have mainly focused on the use of CD8+ T cells (and MHC class I-restricted tumor antigens) are not effective in eliminating cancer cells. Recent interest has been directed towards the use of CD4+ T cells in generating antitumor immunity. To this end, the identification of MHC class II-restricted tumor antigens that can stimulate CD4+ T cells might provide opportunities for developing effective cancer vaccines.

PMID:
11323286
DOI:
10.1016/s1471-4906(01)01896-8
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center